Trastuzumab (herceptine) dans le traitement medical des cancers du sein
Mots-clés :
Cancer du sein; Her 2 neu; thérapie cibléeRésumé
Prérequis : Le trastuzumab est un anticorps monoclonal humanisé qui agit sur le récepteur HER2 neu, surexprimé dans 20% des cancers du sein et qui fait partie du complexe de l’Epidermal Growth Factor Receptor.But : Préciser les connaissances récentes concernant l’utilisation pratique du « Trastuzumab (l’herceptine ®) » dans le cancer du sein.
Méthode : Recherche bibliographique et revue de la littérature effectuées en se référant aux bases de données médicales informatisées (Medline, Science direct) en utilisant les mots clés suivants : cancer du sein (breast cancer), thérapeutique ciblée (targeted therapy), HER2 neu, transtuzumab/herceptine.
Résultats : Le trastuzumab représente une importante avancée thérapeutique dans les cancers du sein et a permis une amélioration de la survie médiane en situation métastatique et une augmentation des survies actuarielle et globale en situation adjuvante. Sa tolérance est bonne avec un risque de toxicité cardiaque qui est rarement rapportée.
Conclusion : Le trastuzumab constitue une avancée thérapeutique pour les cancers du sein.
Téléchargements
Références
Boyle P, Ferley J. Cancer incidence and mortality in Europe. Ann Oncol 2005;16:481-8
Maalej M, Hentati D, Messai T et al. Breast cancer in Tunisia in 2004: a comparative clinical and epidemiological study. Bull Cancer 2008; 95:5-9.
Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Onco. 2005;16:1569-83.
Slamon DJ, Clark GM, Wong SG, Levin WJ. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-82.
Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002; 9:75-85.
Spirig C, Thürlimann B, Huober J. Traitements ciblés dans le cancer du sein. Forum Med Suisse 2008;8: 632-35.
Beuzeboc P. Indications de l'Herceptin® dans le traitement du cancer du sein. Gynecol Obstet Fertil 2004; 32:164-72.
Rampaul R., Pinder S, Gullick W, Robertson J, Ellis I. HER-2 in breast cancer—methods of detection, clinical significance and future prospects for treatment. Crit Rev Oncol Hematol 2002;43: 231-44.
Fagnani F, Colin X, Arveux P et al. Cost effectiveness analysis of adjuvant therapy with trastuzumab in patient with HER2 positive early cancer. Bull cancer 2007;94: 711-20.
Goldenberg M. Trastuzumab, a Recombinant DNA-Derived Humanized Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer. Clin Ther 1999; 2:309-18.
Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001; 28: 4-11.
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45.
Slamon DJ, Leyland-Jones B, Shak S, et al. Addition of herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anti-cancer activity: a randomized multinational controlled phase III trial. Proc Annu Meet Am Soc Clin Oncol. 1998; 17:98.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-84.
Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 over expression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17: 97.
Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC?T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC?TH) with docetaxel,carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Cancer Res 2009;69:500.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84
Baselga J, Perez A, Pienkowski T, Bell R. Adjuvant trstuzumab: a milestone in the treatment of HER-2- positive early breast cancer. Oncologist 2006;11:4-12.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-Positive breast cancer. N Eng J Med 2005;353: 1659-72.
Jackisch C. HER-2-Positive Metastatic Breast cancer: optimizin Trastuzumab-based Therapy. Oncologist 2006; 11:34-41.
Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systemic review. Cancer Treat Rev 2008; 34:539-557.
Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369: 29-36.
Smith I. Trastuzumab following adjuvant chemotherapy in HER2- positive early breast cancer (HERA trial): disease-free and overall survival after 2 year median follow-up. Scientific Special Session, American Society of Clinical Oncology (ASCO) Annual Meeting, 2006; June.
Perez E, Suman V, Davidson N et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008: 26:1231-8.
Perez E, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-9.
Guglin M, Hartlage G, Reynolds C, Chen R, Patel V. Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study. J Card Fail 2009; 15:651-57.
Walji N, Bhatt L, DhalluS, Fernando I. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure. Breast 2008;17: 423-25.
Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783- 92.
Belkacemi Y, Gligorov J, Mauriac L, Azria D. Cancer du sein surexprimant l'oncoprotéine HER2/Neu : comment prescrire le trastuzumab (Herceptin) en situation adjuvante ? Bull cancer 2006;93: 991-9.
Deville L, Desrayaud Jourdan N, Vignot S et al. Les difficultés de prescription de trastuzumab évaluation des non conformes. Bull cancer 2006; 93:637-47.
Perez-Ellis, Carole MSc. Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2 Overexpressed Metastatic Breast Cancer. Am J Clin Oncol 2009;32: 492-98.
Garrison L, Lubeck D, Lalla D, Paton V, Dueck A, Perez E. Cost effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007;110: 489-98.
